Tofacitinib 10 mg + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Sep 16, 2020 → Jan 9, 2021

NCT ID

NCT04469114

About Tofacitinib 10 mg + Placebo

Tofacitinib 10 mg + Placebo is a phase 3 stage product being developed by Pfizer for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04469114. Target conditions include Covid19.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04469114	Phase 3	Completed	Sep 16, 2020	Jan 9, 2021	Covid19

Competing Products

20 competing products in Covid19

See all competitors

Product	Company	Stage	Hype Score
Favipiravir + Nitazoxanide	Strides Pharma	Phase 2	51
Icosapent ethyl	Amarin Corporation	Approved	77
GX-03 + Petrolatum ointment	Turn Therapeutics	Phase 2	44
Cytotoxic T Lymphocytes	Tevogen Bio	Phase 1	25
DS-5670a + Placebo	Daiichi Sankyo	Phase 1/2	41
Pegylated Interferon-α2b	Zydus Lifesciences	Phase 2	52
Baricitinib	Eli Lilly	Phase 3	77
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814	Eli Lilly	Phase 3	77
bamlanivimab	Eli Lilly	Approved	85
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222	AstraZeneca	Phase 1	33
Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo	Novartis	Phase 1/2	41
Pirfenidone	Roche	Pre-clinical	23
Remdesivir + Remdesivir Placebo + Corticosteroid	Gilead Sciences	Phase 3	76
Remdesivir	Gilead Sciences	Pre-clinical	22
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid	Gilead Sciences	Phase 3	76
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)	Pfizer	Phase 3	76
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine	Pfizer	Pre-clinical	22
BNT162b2	Pfizer	Phase 2	51
Anakinra + 0.9% Saline	Swedish Orphan Biovitrum	Phase 2	51
COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)	Sanofi	Approved	84

Other Products from Pfizer